Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival-Reference-Cited by-同舟云学术

Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival

Published:2022-10 Issue:10 Volume:20 Page:2439-2443
ISSN:1538-7836
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:Journal of Thrombosis and Haemostasis

Author:

Gangat Naseema^ORCID,Singh Amritpal^ORCID,Szuber Natasha^ORCID,Begna Kebede^ORCID,Elliott Michelle^ORCID,Wolanskyj‐Spinner Alexandra^ORCID,Hanson Curtis A.^ORCID,Pardanani Animesh^ORCID,De Stefano Valerio^ORCID,Barbui Tiziano^ORCID,Vannucchi Alessandro M.^ORCID,Tefferi Ayalew^ORCID

Publisher

Elsevier BV

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15834

Reference10 articles.

1. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms;De Stefano;Blood Cancer J,2018

2. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria;Finazzi;Leukemia,2012

3. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms;Hamulyák;Blood Adv,2021

4. Practice‐relevant revision of IPSET‐thrombosis based on 1019 patients with WHO‐defined essential thrombocythemia;Barbui;Blood Cancer J,2015

5. A prognostic model to predict survival in 867 World Health Organization‐defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment;Passamonti;Blood,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment;Scientific Reports;2024-07-19

2. A thromboembolic event as the first presentation of essential thrombocytosis: A case report;Thrombosis Research;2024-06

3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25

4. One thousand patients with essential thrombocythemia: the Mayo Clinic experience;Blood Cancer Journal;2024-01-18

5. JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions;Molecular Diversity;2023-11-25